Acrivon Therapeutics GAAP EPS of -$0.42 beats by $0.02

Acrivon Therapeutics (ACRV) reported Q3 GAAP EPS of -$0.42, beating estimates by $0.02. The company has $77.8M in cash and investments, expected to last until Q4 2027. Shares fell 2.05% after hours.

Original reporting
Published Nov 16, 2026, 10:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Acrivon Therapeutics GAAP EPS of -$0.42 beats by $0.02 — source image
Decision brief

The 30-second read

$ACRVBullishMed
01

Why it matters

The EPS beat can improve near-term sentiment, while the stated funding runway into Q4 2027 reduces balance-sheet overhang and may lower perceived dilution risk.

02

Market read

Traders can update positioning around earnings expectations and funding-risk assumptions based on the EPS beat and the runway statement.

03

What to watch

The article does not include revenue, guidance, or segment/clinical catalysts, which are often the primary drivers of post-earnings repricing in biotech.

Relevance 8/10Novelty 8/10Timing: after-hours earnings release (Q3 results)

Background

The piece summarizes Acrivon Therapeutics’ Q3 GAAP EPS result and provides a cash/investments runway estimate.

Company-level read

Ticker impact

$ACRVBullishMedium confidence
Context

Acrivon Therapeutics reported Q3 GAAP EPS of -$0.42, beating by $0.02, and disclosed $77.8M cash/investments expected to fund operations into Q4 2027.

Expected impact

Shares may see modest upside or reduced downside as the market digests the EPS beat and longer funding horizon.

Evidence & confidence

The article provides a concrete earnings datapoint (GAAP EPS beat) plus a balance-sheet runway statement, both directly tied to investor risk and valuation.

Market effects

Biotech investors may recalibrate funding-risk expectations for small-cap drug developers when cash runway is extended.

Limited, single-company earnings impact.

Low, no cross-market policy or macro linkage indicated.

Counterpoint

Despite the EPS beat, the company still reported negative GAAP earnings, so the market may focus on burn rate and whether the runway is sufficient for upcoming clinical or commercialization milestones.

Key entities

  • Acrivon Therapeutics

    Reported Q3 GAAP EPS of -$0.42 (beat by $0.02) and disclosed $77.8M cash, cash equivalents and investments as of Sept. 30, 2026.

Related articles

$ACRVMed

Acrivon Therapeutics, Inc. (ACRV): Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1…

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Regulation FD Disclosure. Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1, Mohamad A. Salkeni2, Neel Gandhi3, Gerald Falchook4, David Sommerhalder5, Benedito A. Carneiro6, Judy Wang7, Monica Mita8,

$ACRVMed

Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach AI-driven AP3 platform was us

$ACRVMedAI 8/10

Acrivon Therapeutics Highlights Phase 2-Ready ACR-525 and Preclinical EoE Programs

Acrivon Therapeutics presented its immunology and inflammation programs, including the Phase 2-ready ACR-525, a selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program, at an R&D event. The company highlighted EoE's growing patient population and treatment gaps as rationale for ACR-525's development, citing favorable early clinical data and safety profile. The presentation is available on the company's investor website.

$ACRVMedAI 8/10

Acrivon to present cancer drug trial data at November symposium

Acrivon Therapeutics (ACRV) will present Phase 1/2 trial data for ACR-2316 at a cancer symposium in November. The study showed clinical activity in endometrial and lung cancers, with one patient achieving complete response. The trial has progressed to dose expansion, including pancreatic cancer patients. ACRV uses its AP3 platform to predict patient responses.

$ACRVMedAI 8/10

Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing

Acrivon Therapeutics (ACRV) announced the advancement of ACR-7280, an oral CDK11 inhibitor, as its next development candidate. The company plans to file an IND application for the drug with the FDA in the first half of 2027. ACR-7280 showed complete tumor regression in AML xenograft models and potential in combination therapies. Acrivon's lead program, ACR-368, is in a Phase 2 trial for endometrial cancer.